Simcha Therapeutics Presents Preclinical Data Demonstrating Potential for Decoy-Resistant IL-18 to Enhance Efficacy of Bi-specific T-cell Engagers
SOUTH SAN FRANCISCO, Calif., and NEW HAVEN, Conn., Oct. 21, 2025 (GLOBE NEWSWIRE) — Simcha Therapeutics (“Simcha”), a clinical-stage immunobiology company pioneering first-in-class cytokine treatments for cancer, today announced the presentation of preclinical results which demonstrate enhanced efficacy from combining decoy-resistant IL-18 (DR-18), ST-067, with bispecific T-cell engagers (BiTEs) in multiple solid and hematologic cancer […]